TAC1 and rosacea: It has demonstrated efficacy in addressing persistent erythema and flushing associated with rosacea by inhibiting mast cell degranulation and acetylcholine release, while also modulating substance P, calcitonin gene‐related peptide, and vasoactive intestinal peptide [19].